Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

A growing measles outbreak in west Texas has infected 48 people, according to official state data released Thursday -- the ...

The rise of misinformation online has helped fringe health ideas go mainstream and eased RFK Jr.'s path to confirmation as ...

Louisiana’s surgeon general said in a memo Thursday that the state would “encourage each patient to discuss the risks and benefits of vaccination with their provider” but would “no longer promote mass ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...

Increase in ER Visits, Hospital Admissions is Driven by Flu; IDPH Urges Public To Quickly Seek Testing and Treatment if they Experience Flu-like Symptoms The Illinois Department of Public Health (IDPH ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Nine of 24 people with measles in Texas are hospitalized for a disease that was considered eliminated in 2000. Kennedy has ...

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...